(c) 2024 PillSync.com

fingolimod 0.25 MG Oral Capsule Gilenya

1 INDICATIONS AND USAGE GILENYA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )

Novartis Pharmaceuticals Corporation


5 years ago CAPSULE WHITE FTY 0 25 mg fingolimod 0.25 MG Oral Capsule Gilenya

CAPSULE WHITE FTY 0 25 mg

16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied 0.25 mg GILENYA capsules are supplied as follows: hard gelatin capsules with an ivory opaque body and cap, with black radial imprint “FTY 0.25 mg” on the cap and a black radial band on the capsule body Carton of 7 capsules containing 1 blister card of 7 capsules per blister card NDC 0078-0965-89 0.5 mg GILENYA capsules are supplied as follows: hard gelatin capsules with a white opaque body and bright yellow cap imprinted with “FTY 0.5 mg” on the cap and 2 radial bands imprinted on the capsule body with yellow ink. Bottle of 30 capsules NDC 0078-0607-15 16.2 Storage and Handling GILENYA capsules should be stored at 20ÂșC to 25ÂșC (68ÂșF to 77ÂșF); excursions permitted to 15ÂșC to 30ÂșC (59ÂșF to 86ÂșF). Protect from moisture.


More pills like CAPSULE FTY 0 25 mg












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site